ESMO 2024 Late-Breaking Data: Phase III ARANOTE Trial Shows NUBEQA® (darolutamide ...

NUBEQA® (darolutamide) + ADT showed significant improvement in rPFS vs. placebo + ADT in mHSPC patients, presented at 2024 ESMO Congress.